These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 17203810)

  • 41. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study.
    Hanefeld M; Marx N; Pfützner A; Baurecht W; Lübben G; Karagiannis E; Stier U; Forst T
    J Am Coll Cardiol; 2007 Jan; 49(3):290-7. PubMed ID: 17239709
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Positive correlation of CRP and fibrinogen levels as cardiovascular risk factors in early stage of continuous ambulatory peritoneal dialysis patients.
    Tekin IO; Pocan B; Borazan A; Ucar E; Kuvandik G; Ilikhan S; Demircan N; Ozer C; Kadayifci S
    Ren Fail; 2008; 30(2):219-25. PubMed ID: 18300125
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Level of high-sensitivity C-reactive protein in Saudi patients with chronic stable coronary artery disease.
    Habib SS
    J Ayub Med Coll Abbottabad; 2008; 20(2):3-6. PubMed ID: 19385446
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The role of C-reactive protein as an inflammatory marker in gastrointestinal diseases.
    Vermeire S; Van Assche G; Rutgeerts P
    Nat Clin Pract Gastroenterol Hepatol; 2005 Dec; 2(12):580-6. PubMed ID: 16327837
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Usefulness of combining serum uric acid and C-reactive protein for risk stratification of patients with coronary artery disease (Bezafibrate Infarction Prevention [BIP] study).
    Brodov Y; Behar S; Goldenberg I; Boyko V; Chouraqui P
    Am J Cardiol; 2009 Jul; 104(2):194-8. PubMed ID: 19576345
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of withdrawal of pravastatin therapy on C-reactive protein and low-density lipoprotein cholesterol.
    van der Harst P; Asselbergs FW; Hillege HL; Bakker SJ; Voors AA; van Veldhuisen DJ; van Gilst WH;
    Am J Cardiol; 2007 Nov; 100(10):1548-51. PubMed ID: 17996517
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Jupiter study, CRP screening, and aggressive statin therapy-implications for the primary prevention of cardiovascular disease.
    Kones R
    Ther Adv Cardiovasc Dis; 2009 Aug; 3(4):309-15. PubMed ID: 19460829
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22.
    Ray KK; Cannon CP; Cairns R; Morrow DA; Ridker PM; Braunwald E
    Arterioscler Thromb Vasc Biol; 2009 Mar; 29(3):424-30. PubMed ID: 19122170
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease.
    Sabatine MS; Morrow DA; O'Donoghue M; Jablonksi KA; Rice MM; Solomon S; Rosenberg Y; Domanski MJ; Hsia J;
    Arterioscler Thromb Vasc Biol; 2007 Nov; 27(11):2463-9. PubMed ID: 17766330
    [TBL] [Abstract][Full Text] [Related]  

  • 50. C-reactive protein, cardiovascular disease and stroke: new roles for an old biomarker.
    Willcox BJ; Abbott RD; Yano K; Rodriguez BL; Willcox DC; Curb JD
    Expert Rev Neurother; 2004 May; 4(3):507-18. PubMed ID: 15853546
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [The role of C-reactive protein and other acute phase markers in atherosclerosis].
    Gusev DE; Ponomar' EG
    Klin Med (Mosk); 2006; 84(5):25-30. PubMed ID: 16827274
    [TBL] [Abstract][Full Text] [Related]  

  • 52. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: report from the clinical practice discussion group.
    Smith SC; Anderson JL; Cannon RO; Fadl YY; Koenig W; Libby P; Lipshultz SE; Mensah GA; Ridker PM; Rosenson R; ;
    Circulation; 2004 Dec; 110(25):e550-3. PubMed ID: 15611380
    [No Abstract]   [Full Text] [Related]  

  • 53. [Age related macular degeneration and C-reactive protein].
    Stefan C; Dumitrica DM; Tebeanu E; Sapundgieva A; Dragomir L; Cristea I
    Oftalmologia; 2008; 52(3):73-6. PubMed ID: 19149122
    [TBL] [Abstract][Full Text] [Related]  

  • 54. C-reactive protein, insulin resistance and risk of cardiovascular disease: a population-based study.
    Jeppesen J; Hansen TW; Olsen MH; Rasmussen S; Ibsen H; Torp-Pedersen C; Hildebrandt PR; Madsbad S
    Eur J Cardiovasc Prev Rehabil; 2008 Oct; 15(5):594-8. PubMed ID: 18753952
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Homocysteine-lowering therapy does not affect inflammatory markers of atherosclerosis in patients with stable coronary artery disease.
    Bleie Ø; Semb AG; Grundt H; Nordrehaug JE; Vollset SE; Ueland PM; Nilsen DW; Bakken AM; Refsum H; Nygård OK
    J Intern Med; 2007 Aug; 262(2):244-53. PubMed ID: 17645592
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Serum chitotriosidase activity, a marker of activated macrophages, predicts new cardiovascular events independently of C-reactive protein.
    Artieda M; Cenarro A; Gañán A; Lukic A; Moreno E; Puzo J; Pocoví M; Civeira F
    Cardiology; 2007; 108(4):297-306. PubMed ID: 17290100
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Change in cardiovascular risk status after dental clearance.
    Ellis JS; Averley PA; Preshaw PM; Steele JG; Seymour RA; Thomason JM
    Br Dent J; 2007 May; 202(9):543-4. PubMed ID: 17496863
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Relation of C-reactive protein to obesity, adipose tissue hormones and cardiovascular risk factors in men treated with early percutaneous intervention in course of acute myocardial infarction.
    Piestrzeniewicz K; Łuczak K; Komorowski J; Jankiewicz-Wika J; Goch JH
    Neuro Endocrinol Lett; 2007 Aug; 28(4):427-32. PubMed ID: 17693973
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Atrial fibrillation and CHADS2 risk factors are associated with highly sensitive C-reactive protein incrementally and independently.
    Crandall MA; Horne BD; Day JD; Anderson JL; Muhlestein JB; Crandall BG; Weiss JP; Lappé DL; Bunch TJ
    Pacing Clin Electrophysiol; 2009 May; 32(5):648-52. PubMed ID: 19422587
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Association of endogenous sex hormone with C-reactive protein levels in middle-aged and elderly men.
    Nakhai Pour HR; Grobbee DE; Muller M; van der Schouw YT
    Clin Endocrinol (Oxf); 2007 Mar; 66(3):394-8. PubMed ID: 17302874
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.